AtriCure, Inc.

AtriCure, Inc.'s next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, AtriCure, Inc. has 50.86M shares outstanding.

As of June 30, 2026, AtriCure, Inc. maintains a current ratio of 4.22, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.76, indicating elevated leverage, while an interest coverage ratio of 5.99 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, AtriCure, Inc. posted a return on equity (ROE) of 2.15, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 1.99 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.64, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.74, useful for judging operating efficiency across full business cycles. The company generates approximately 372,777.67 in revenue per employee across its workforce of 1,337.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.68 indicates how many times AtriCure, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, AtriCure, Inc. recorded 1.35M in income tax expense. That works out to an effective tax rate of 12.75, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 10.59M, leaving 9.24M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, AtriCure, Inc. generated 498.59M in revenue and converted that into 9.24M in net income, yielding earnings per share of 0.19. EBITDA reached 29.54M, while operating income came in at 11.28M.

As of June 30, 2026, AtriCure, Inc. holds 146.86M in cash and equivalents against 62.19M in total debt, resulting in a net debt position of -93.47M. Total book value stands at 452.03M, with working capital of 230.74M providing operational flexibility.

AtriCure, Inc. produced 56.84M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -11.23M in capital expenditures, free cash flow totaled 45.62M - equivalent to 0.94 per share.

Over the twelve months ended June 30, 2026, AtriCure, Inc. posted a gross margin of 76.30, reflecting its pricing power and cost economics. The operating margin of 2.26 and net profit margin of 1.85 provide insight into operational efficiency.